LAUSR

OBJECTIVES The main aim of the study was to develop an economical, insightful,accurate and simple RP-HPLC-DAD method with high precision and good sensitivity for concurrent determination of Tenofovir disoproxil fumarate, Doravirine and Lamivudine in blended bulk form and their combined tablet form. MATERIAL AND METHODS A method with Ascentis C18 (150 x 4.6mm, 5μm) column, mobile phase ratio of 0.1% ortho phosphoric acid and Acetonitrile in 70:30 (v/v), 1ml/min flow rate and detection wavelength of 260nm was highly proficient in effective separation of all three drugs. The developed method was validated in accordance with ICH specifications. RESULTS The retention times of Doravirine, Lamivudine and Tenofovir disoproxil fumarate observed were 2.4, 2.9, and 3.6 min respectively. The linear responses were observed for Doravirine, Lamivudine and Tenofovir disoproxil fumarate in the range of 12.5-75 μg/ml, 75-225μg/ml and 75-225μg/ml respectively. The limit of detection and quantification values were calculated to be 0.36μg/ml and 0.11μg/ml for Lamivudine, 0.55μg/ml and 1.66 μg/ml for Tenofovir disoproxil fumarate and 0.03 μg/ml and 0.09μg/ml for Doravirine. The %RSD values of the intraday and inter-day precision were calculated in the range of 0.134-1.749. The mean percentage recovery of all three analytes was in the range of 98.85% - 100.18%. The statistical results of the validation parameters ensured that the method was accurate, specific, and precise with good sensitivity. Investigation of analytes under different stressed conditions ensures the stability of analytes reflecting the stability indication of the method. The developed method has high proficiency in separation of Tenofovir disoproxil fumarate, Doravirine and Lamivudine. The degradation products generated due to stress conditions also separated with good resolution. CONCLUSION The current method is a stability-indicating assay method consisting of appropriate specificity, accuracy, precision and sensitivity. The developed method has a good potential to be adopted by the pharmaceutical industrial sector.